Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials

Aaron Mansfield, James T. Symanowski, Tobias D Peikert

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Rationale: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. Objectives: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. Methods: We searched PubMed for "mesothelioma" with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95% confidence intervals (95% CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. Measurements and main results: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27% of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5%), 203 with biphasic tumors (13.8%), 137 with sarcomatoid tumors (9.3%) and 124 with unknown subtypes (8.4%). In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (. n=. 137) 19 responses were observed. This accounted for 5.9% of all responses and yields a 13.9% (95% CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. Conclusion: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.

Original languageEnglish (US)
Pages (from-to)133-136
Number of pages4
JournalLung Cancer
Volume86
Issue number2
DOIs
StatePublished - Nov 1 2014

Fingerprint

Clinical Trials
Mesothelioma
Neoplasms
Confidence Intervals
Publications
Malignant Mesothelioma
Asbestos
Therapeutics
PubMed
Histology
Biomarkers
Gene Expression

Keywords

  • Epithelioid
  • Mesothelioma
  • Response rates
  • Sarcomatoid
  • Systematic review
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. / Mansfield, Aaron; Symanowski, James T.; Peikert, Tobias D.

In: Lung Cancer, Vol. 86, No. 2, 01.11.2014, p. 133-136.

Research output: Contribution to journalArticle

@article{efd6abd11a014680b3d10d8d327807b2,
title = "Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials",
abstract = "Rationale: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. Objectives: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. Methods: We searched PubMed for {"}mesothelioma{"} with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95{\%} confidence intervals (95{\%} CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. Measurements and main results: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27{\%} of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5{\%}), 203 with biphasic tumors (13.8{\%}), 137 with sarcomatoid tumors (9.3{\%}) and 124 with unknown subtypes (8.4{\%}). In total, there were 323 responses (21.9{\%}, complete and partial responses, 95{\%} CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (. n=. 137) 19 responses were observed. This accounted for 5.9{\%} of all responses and yields a 13.9{\%} (95{\%} CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. Conclusion: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.",
keywords = "Epithelioid, Mesothelioma, Response rates, Sarcomatoid, Systematic review, Tumor",
author = "Aaron Mansfield and Symanowski, {James T.} and Peikert, {Tobias D}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.lungcan.2014.08.017",
language = "English (US)",
volume = "86",
pages = "133--136",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials

AU - Mansfield, Aaron

AU - Symanowski, James T.

AU - Peikert, Tobias D

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Rationale: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. Objectives: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. Methods: We searched PubMed for "mesothelioma" with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95% confidence intervals (95% CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. Measurements and main results: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27% of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5%), 203 with biphasic tumors (13.8%), 137 with sarcomatoid tumors (9.3%) and 124 with unknown subtypes (8.4%). In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (. n=. 137) 19 responses were observed. This accounted for 5.9% of all responses and yields a 13.9% (95% CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. Conclusion: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.

AB - Rationale: Malignant pleural mesothelioma is an almost universally fatal malignancy primarily related to asbestos exposure. Based on the differences in immunologic markers and gene expression between histologic subtypes of mesothelioma, and our clinical impression that response rates vary by histology, we decided to examine the reported response rates of mesothelioma subtypes. Objectives: Our objective was to compare the response rates of sarcomatoid mesotheliomas to the overall response rates in published clinical trials. Methods: We searched PubMed for "mesothelioma" with the clinical trials filter selected. We included articles published between January 1, 2000 and March 20, 2014 in which subjects received first or second line systemic therapy for malignant pleural mesothelioma. Studies investigating multi-modality therapy including surgery were excluded. Response rates [including 95% confidence intervals (95% CI)] were estimated for the entire patient cohort and then separately for subjects with sarcomatoid tumors. Measurements and main results: We reviewed 544 publications of which 41 trials met our inclusion criteria. Eleven of these trials did not include patients with sarcomatoid mesothelioma (27% of eligible studies). The remaining 30 publications included 1475 subjects, 1011 with epithelioid tumors (68.5%), 203 with biphasic tumors (13.8%), 137 with sarcomatoid tumors (9.3%) and 124 with unknown subtypes (8.4%). In total, there were 323 responses (21.9%, complete and partial responses, 95% CI: 16.3, 28.8) to systemic therapy across all histological subtypes. In patients with sarcomatoid tumors (. n=. 137) 19 responses were observed. This accounted for 5.9% of all responses and yields a 13.9% (95% CI: 8.6, 21.6) response rate for patients with sarcomatoid tumors. Multiple biases likely affected this systematic review. Conclusion: Response rates for different histological subtypes of malignant pleural mesothelioma are infrequently reported. Partial and complete responses to systemic therapies appear to be less common among patients with sarcomatoid tumors.

KW - Epithelioid

KW - Mesothelioma

KW - Response rates

KW - Sarcomatoid

KW - Systematic review

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84908398824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908398824&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.08.017

DO - 10.1016/j.lungcan.2014.08.017

M3 - Article

C2 - 25217189

AN - SCOPUS:84908398824

VL - 86

SP - 133

EP - 136

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -